Lauria Giuseppe, Ziegler Dan, Malik Rayaz, Merkies Ingemar S J, Waxman Stephen G, Faber Catharina G
Neuroalgology and Headache Unit, IRCCS Foundation "Carlo Besta" Neurological Institute, Via Celoria, 11, 20133, Milan, Italy,
Curr Diab Rep. 2014 Oct;14(10):538. doi: 10.1007/s11892-014-0538-5.
Painful neuropathies are frequently encountered in clinical practice as an early or late complication of several systemic disorders. Among them, diabetes is one of the most important due to its epidemiology and the relevance for regulatory agencies in the assessment of efficacy of new analgesics. However, the presentation and course of painful neuropathies, as well as the response to available drugs, are highly variable and unpredictable, posing significant challenges in the management of patients. Experimental and clinical studies have suggested that polymorphisms and mutations in pain-related genes are involved in the facilitation or inhibition of nociception, and might modulate neuropathic pain and the response to analgesics in patients. Voltage-gated sodium channel genes are among the most relevant, due to the key role of these membrane proteins in the physiology of nociception and their involvement in the pathogenesis of idiopathic painful small fiber neuropathies. These compelling features make sodium channel candidate targets for a novel approach to painful diabetic and idiopathic neuropathies, which will hopefully allow a new classification of patients and more effective targeted treatments.
在临床实践中,疼痛性神经病变常作为多种全身性疾病的早期或晚期并发症出现。其中,糖尿病因其流行病学特征以及对监管机构评估新型镇痛药疗效的相关性,成为最重要的病因之一。然而,疼痛性神经病变的表现、病程以及对现有药物的反应高度可变且不可预测,给患者的管理带来了重大挑战。实验和临床研究表明,疼痛相关基因的多态性和突变参与伤害感受的促进或抑制,并可能调节患者的神经性疼痛和对镇痛药的反应。电压门控钠通道基因是最相关的基因之一,因为这些膜蛋白在伤害感受生理学中起关键作用,且参与特发性疼痛性小纤维神经病变的发病机制。这些引人注目的特征使钠通道成为治疗疼痛性糖尿病性和特发性神经病变新方法的候选靶点,有望实现患者的新分类和更有效的靶向治疗。